Press Release / May 04, 2020
Hovione Announces the Appointment of Jean-Luc Herbeaux as Chief Operating Officer
Effective May 1st, 2020
Press Room
Press Release / Sep 20, 2019
Hovione announces successful end-of-phase 2 meeting with the FDA and outlines phase 3 program for minocycline topical gel
Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of moderate to severe inflammatory rosacea.
Press Release / Sep 05, 2019
Hovione celebrates its 60th Anniversary in Cork
Loughbeg, Co. Cork. Thursday, September 5th, 2019: Hovione is celebrating its 60th Anniversary today in its site in Cork.
Press Release / Jan 25, 2019
Hovione issues $50 million bond
Hovione has issued a bond of $50 million US dollars maturing in 2033.
Press Release / Oct 17, 2018
Hovione increases production capacity
‘One Site Shop’ expands to respond to growing demands
Press Release / Mar 19, 2018
Hovione reports on recent capacity expansion and future plans to support growth
Hovione reported today recent capacity expansion and future plans in its sites in Portugal, Ireland and New Jersey.
Press Release / Mar 08, 2018
Compliance at Hovione - Annual Inspection Review
Hovione announced today that in the last year their manufacturing facilities were the object of eight inspections, performed by different Health Authorities.
Press Release / Mar 07, 2018
Hovione sells the iMAX business
Hovione announces that it has concluded the sale of all of the share capital of iMAX Diagnostic Imaging limited.
Press Release / Jan 24, 2018
Hovione strengthens Inhalation Services portfolio
Hovione announced that a new MG2 Tekna Precision Capsule filling unit is now online in its Portugal facilities
Press Release / Dec 04, 2017
Hovione Announces Enrollment of First Patient in MARS
A Phase 2 Clinical Trial for the Treatment of Moderate to Severe Inflammatory Rosacea with its Proprietary Minocycline Topical Gel
Contact Us
If you would like to learn more about Hovione, kindly fill in the form below and we will be revert to you soon.